ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Liquidity and Going Concern (Details) $ in Thousands, € in Millions			1 Months Ended	6 Months Ended
	Jan. 03, 2023 USD ($)	Jan. 03, 2023 EUR (€)	Jan. 31, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Cash and cash equivalents
Proceeds from issuance of shares and warrants and warrant exercises, net				$ 113,800
Net loss				(81,040)	$ (39,714)
Accumulated deficit				(549,626)		$ (468,586)
Cash and cash equivalents				$ 122,197		$ 49,898
Substantial Doubt about Going Concern, within One Year				false
Advanz Pharma | License and Supply Agreement
Cash and cash equivalents
Upfront payment received	$ 10,700	€ 10.0	$ 10,700